Home
overview
The rapid increase in drug resistant pathogens, alongside the threat of emerging and re-emerging infectious diseases has posed major challenges to drug discovery researchers globally.

SMi’s forthcoming conference “Superbugs & Superdrugs: A Focus on Anti-Infectives” will address the issues associated with virulent and uncontrollable infectious diseases such as MRSA, VRE, HIV & Hepatitis C. We will also overview current research paradigms and look at new and novel approaches to anti-microbial discovery. In addition to this we will assess the role functional genomics is playing in drug discovery and discuss the future for anti-biotic research.

A unique opportunity to learn from leading industry experts including:
Dr David Payne, Director, Microbiology, GlaxoSmithKline
Dr John Barrett, Senior Director, Antibacterial Drug Discovery, Merck
Dr Beat Weidmann, Head, Infectious Diseases, Preclinical Research, Novartis
Prof Malcolm Page, Head, Biology, Basilea Phamaceutica
Dr William Weiss, Principal Research Scientist, Group Leader, Wyeth Research
Dr Richard Bax, Vice President & Chief Scientific Officer, Biosyn
Prof Ian Chopra, Professor, Microbiology & Director, Antimicrobial Research Centre, University of Leeds
Dr Stephen Hawser, Director, Biology, Arpida
Dr Gordon Foulkes, Executive Vice President, Research & Development, Elitra
Dr Andrew Waller, Group Leader, Biology, British Biotech
Dr Mark Nelson, Senior Director, Exploratory Chemistry, Paratek Pharmaceuticals

Benefits of Attending:
· Genomics: understand the function of genomics in drug discovery
· Antibiotics - old or new? learn where progress is being made
· Natural products: discover their application in targeted drug discovery
· Business development: gain insight into the present and future in the antimicrobial industry
· Building an anti-infectives business: learn from experienced industry leaders

“…An important series of meetings that are well recognised externally…”
Professor Ian Chopra, University of Leeds

Conference programme

8:30 Registration and Coffee

9:00 Chairmen's Opening Remarks

Prof Ian Chopra

Prof Ian Chopra, Professor, Microbiology & Director, Antimicrobial Research Centre, University of Leeds

Dr Richard Bax

Dr Richard Bax, Chief Scientific Officer, Biosyn

Dr Richard Bax

Dr Richard Bax, Chief Scientific Officer, Biosyn

9:10 SUPERBUGS & SUPERDRUGS

Dr Jeffrey Stein

Dr Jeffrey Stein, Chief Scientific Officer, Quorex Pharmaceuticals

  • Emerging superbugs: threats and opportunities
  • Understand molecular & cellular mechanisms of resistance
  • New targets and creative approaches for treatment
  • Anti-infective drug discovery: the need for speed
  • 9:40 MULTIPLE DRUG RESISTANCE

    Dr Beat Weidmann

    Dr Beat Weidmann, Head, Infectious Diseases, Preclinical Research, Novartis

  • MRSA & VRE
  • Pathogenicity and transmission
  • Impact, problems and revolution
  • Controlling and preventing resistance
  • Developing new antibacterials: the current state
  • Will new antibiotics solve the resistance problem? The case for PDF-inhibitors
  • 10:20 MECHANISMS OF ANTIBIOTIC RESEARCH IN THE SUPERBUG S.Aureus

    Dr Alex O’Neill

    Dr Alex O’Neill, Post-Doctoral Research Fellow, University of Leeds

  • Resistance to linezolid and vancomycin arrive
  • Exogenous and endogenous sources of antibiotic resistance in S.Aureus
  • Re-evaluation of unexploited antibiotics
  • Exploitation of existing (validated) targets
  • Exploitation of existing drug-binding pockets
  • 11:00 Morning Coffee

    11:20 ANTI-SENSE DISCOVERY PLATFORM

    Dr Gordon Foulkes

    Dr Gordon Foulkes, Executive Vice President, Research & Development, Elitra Pharmaceuticals

  • Introductions to anti-sense technology
  • Target ID
  • Target prioritization
  • Hypersensitive screens
  • Mechanism-based whole-cell screens
  • 12:00 BACTERIAL TARGETS TO ANTIMICROBIAL LEADS

    Dr Bruce Rogers

    Dr Bruce Rogers, Senior Director, Anti-Infectives Research, Genome Therapeutics

  • New target discovery using genomics
  • Antibacterial targets and validation
  • Hits from screening and compound profiling
  • Molecular tools for rapid MOA determination
  • Success plus challenges
  • 12:40 Lunch

    13:40 GENOME-WIDE DRUG SCREENING

    Dr Phil Youngman

    Dr Phil Youngman, Vice President, Discovery Biology, Elitra Pharmaceuticals

  • Introduction to the Fitness Test concept
  • Screening all targets simultaneously
  • Anti-fungal and anti-bacterial Fitness Testing
  • Determining mechanism of action
  • De-replication of natural products
  • A tool for guiding lead-optimization chemistry
  • 14:20 DEVELOPING A NEW CLASS OF ANTIBIOTICS

    Dr Andrew Waller

    Dr Andrew Waller, Group Leader, Biology, British Biotech

  • The potential of metalloenzymes as anti-bacterial targets
  • Use of targeted metalloenzyme inhibitor libraries
  • PDF inhibitors, a potential new class of antibiotics
  • Challenges and progress
  • Promises for the future
  • 15:00 APPROACHING ANTIBIOTIC RESEARCH

    Dr David Knowles

    Dr David Knowles, Chief Scientific Officer, RiboTargets

  • Conducting antibiotic research
  • Targeting the ribosome “Ribotargets”
  • Challenges and outlook for this new technology
  • State of research across pharmaceutical companies
  • Where will this technology lead antibiotic research?
  • 15:40 Afternoon Tea

    16:00 SURVIVAL OF ANTIBIOTIC RESEARCH

    Dr John Barrett

    Dr John Barrett, Senior Director, Antibacterial Drug Discovery, Merck

  • Infectious diseases, an ever changing panorama
  • Medical need vs business need
  • Clinical requirements of antibiotics
  • Research initiatives
  • Business opportunities
  • Where is the antibiotic research being done?

    Ensuring the continuation of antibiotic research

  • 16:40 HIV & AIDS

    Prof Helga Ruebsamen-Waigmann

    Prof Helga Ruebsamen-Waigmann, Director, Anti-Viral Research, Bayer

  • Understanding and researching HIV & AIDS
  • Drug pipeline
  • HIV fusion inhibitors
  • Reverse transcripase drugs
  • Creating drugs without side effects
  • 17:20 Chairmen's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Mark Nelson

    Dr Mark Nelson, Senior Director, Exploratory Chemistry, Paratek Pharmaceuticals

    9:10 ICLAPRIM

    Dr Stephen Hawser

    Dr Stephen Hawser, Director, Biology, Arpida

  • The resistance problem
  • Developing new drugs to combat resistance
  • Iclaprim, a novel broad-spectrum antibiotic
  • 9:40 PHARMACOKINETICS & PHARMACODYNAMICS

    Dr William Weiss

    Dr William Weiss, Principal Research Scientist, Group Leader, Wyeth Research

  • Establishing pharmacodynamic parameters
  • Dosing regimens
  • Free vs bound drug
  • Use in setting breakpoints
  • Monte Carlo simulations
  • 10:20 ANTI-VIRALS

    Margaret Walsh

    Margaret Walsh, Head, Business Development, Arrow Therapeutics

  • Where else in anti-virals?
  • Commercial opportunities
  • Clinical need
  • Case study: Hepatitis C
  • Case study: Respiratory Syncytial Virus
  • 11:00 Morning Coffee

    11:20 ANTIMICROBIAL RESEARCH & DEVELOPMENT

  • Review of last 25 years
  • Trends and predictions for the next 5 years
  • Products, people and processes
  • Industry trends
  • Dr Richard Bax

    Dr Richard Bax, Chief Scientific Officer, Biosyn

    Dr Richard Bax

    Dr Richard Bax, Chief Scientific Officer, Biosyn

    12:00 TARGETING NON-MULTIPLYING LATENT BACTERIA

    Prof Anthony Coates

    Prof Anthony Coates, Professor of Medical Microbiology, St George’s Hospital Medical School and Biotherapies

  • New strategy targeting non-multiplying latent bacteria
  • A review of the importance of non-multiplying bacteria
  • Shortening the duration of chemotherapy and reducing emergence of antimicrobial resistance
  • New tests and new terminology
  • 12:40 Lunch

    14:00 BACTERIAL GENOMICS TO DELIVER NEW ANTIBIOTICS

    Dr David Payne

    Dr David Payne, Director, Microbiology, GlaxoSmithKline

  • Exploiting multiple genomes for new target discovery
  • Target validation of novel antibacterial targets
  • Target examples:some surprises, successes and failures
  • Screening - what went wrong and what can we do about it?
  • Has genomics delivered?
  • 14:40 NATURAL PRODUCTS & ANTI-INFECTIVE RESEARCH

    Prof Malcolm Page

    Prof Malcolm Page, Head, Biology, Basilea Phamaceutica

  • Evolution & natural products
  • New approaches to natural product discovery
  • Current leads
  • Can natural products still deliver effective drugs?
  • 15:20 Afternoon Tea

    15:40 THE RIBOSOME AS A DRUG TARGET

    Dr Joyce Sutcliffe

    Dr Joyce Sutcliffe, Vice President, Biochemistry & Molecular Biology, Rib-X Pharmaceuticals

  • Obtaining high resolution crystal structures
  • Structure based drug design
  • Identifying drug targets
  • Can the ribosome deliver anti-infectives?
  • Genomics vs ribosomes
  • 16:20 ESTABLISHING A NEW ANTIBIOTIC COMPANY

    Dr Lloyd Czaplewski

    Dr Lloyd Czaplewski, Director, Research, Prolysis

  • Exploiting biology in antibiotic discovery
  • Building and finacing a new antibiotic research and development company
  • Demonstrating effective technology development
  • Creating new product opportunities
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.